• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Chinese Journal of Contemporary Neurology and Neurosurgery >Progress of translational research on the pathogenesis, diagnosis and treatment of Parkinson's disease
【24h】

Progress of translational research on the pathogenesis, diagnosis and treatment of Parkinson's disease

机译：帕金森病的发病机制，诊断和治疗的转化研究进展

获取原文
       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Because of its high prevalence, severe disability and chronic course of disease, it has become one of the most important research focuses in modern medicine ranging from early diagnosis and treatment to prevention. During the period of Twelfth Five?Year Plan for National Economic and Social Development, our team made use of previously established PD Clinical Databse and applying basic research platform, focused on clinical and basic development of PD, and further extended our investigation into the field of pathogenesis, diagnosis and treatment in PD with characteristics of translational medicine. Several progresses have been made in a multiple of aspects: 1) a novel cellular mechanism of mitochondrial fission with the involvement of VPS35 gene, dysregulation of which might be involved in the pathogenesis of familial and sporadic PD. 2) The predictive value of autonomic ysfunction and dopamine transporter (DAT) PET in identifying patients with idiopathic rapid eye movement sleep behavior disorder (iRBD) with a high risk of progressing into neurodegenerative synucleinopathy diseases could form a basis for future disease?- prevention trials. Additionally, we initiated the research on PD mortality rate and analyzed the common reasons of death, which added to the evidence of clinical prognosis and progression. 3) We issued the first, second and third versions of "Chinese guidelines for treatment of Parkinson's disease", as well as the "Diagnostic criteria of Parkinson's disease in China (2016 edition)", which could help improve the diagnostic ability and optimize the clinical treatment of PD in China. DOI: 10.3969/j.issn.1672-6731.2018.01.003.
机译：帕金森氏病（PD）是最常见的神经退行性疾病之一。由于它的高患病率，严重的残疾和慢性病程，它已成为从早期诊断和治疗到预防的现代医学最重要的研究重点之一。在国民经济和社会发展“十二五”规划期间，我们的团队利用先前建立的PD临床数据库并应用基础研究平台，专注于PD的临床和基础发展，并将我们的研究进一步扩展到PD具有转化医学特点的发病机制，诊断和治疗。在多个方面已经取得了一些进展：1）线粒体裂变的新型细胞机制与VPS35基因有关，其失调可能与家族性和散发性PD的发病机理有关。 2）自主神经功能障碍和多巴胺转运蛋白（DAT）PET在识别患有发展为神经退行性突触核蛋白病疾病的高风险的特发性快速眼动睡眠行为障碍（iRBD）患者中的预测价值可为未来疾病的预防奠定基础-预防试验。此外，我们启动了PD死亡率的研究并分析了死亡的常见原因，这增加了临床预后和进展的证据。 3）我们发布了《中国帕金森氏病治疗指南》的第一版，第二版和第三版，以及《中国帕金森氏病诊断标准》（2016年版），有助于提高诊断能力并优化诊断。 PD在中国的临床治疗。 DOI：10.3969 / j.issn.1672-6731.2018.01.003。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号